Cargando…

Targeting RAF Isoforms and Tumor Microenvironments in RAS or BRAF Mutant Colorectal Cancers with SJ-C1044 for Anti-Tumor Activity

Colorectal cancer (CRC) is a significant global health issue characterized by a high prevalence of KRAS gene mutations. The RAS/MAPK pathway, involving KRAS, plays a crucial role in CRC progression. Although some RAS inhibitors have been approved, their efficacy in CRC is limited. To overcome these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Sungpyo, Jeon, Myeongjin, Kwon, Jeonghee, Park, Hanbyeol, Lee, Goeun, Kim, Kilwon, Ahn, Soonkil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378394/ https://www.ncbi.nlm.nih.gov/pubmed/37504287 http://dx.doi.org/10.3390/cimb45070371

Ejemplares similares

Targeting FAK/PYK2 with SJP1602 for Anti-Tumor Activity in Triple-Negative Breast Cancer
por: Jeon, Myeongjin, et al.
Publicado: (2023)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
por: Yuan, Xi, et al.
Publicado: (2020)

Inhibition of mutant RAS-RAF interaction by mimicking structural and dynamic properties of phosphorylated RAS
por: Ilter, Metehan, et al.
Publicado: (2022)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019)

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
por: Portelinha, Ana, et al.
Publicado: (2021)

RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
por: Jin, Ting, et al.
Publicado: (2017)

Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
por: Trebino, Tarah, et al.
Publicado: (2023)

Triple concerto BWV 1044 : for flute, violin and harpsichord in full score /

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy
por: Cristofani, Riccardo, et al.
Publicado: (2022)

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer
por: Thomsen, Caroline Emilie B., et al.
Publicado: (2017)

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
por: Vakana, Eliza, et al.
Publicado: (2016)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
por: Bollag, Gideon, et al.
Publicado: (2010)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
por: Pan, Jing-hua, et al.
Publicado: (2018)

Concerti pour clavecin BWV 1044, 1052, 1054
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1994)

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition
por: Allen, Amy, et al.
Publicado: (2019)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2015)

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
por: Girotti, Maria Romina, et al.
Publicado: (2017)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Ras and Raf pathways in epidermis development and carcinogenesis
por: Kern, F, et al.
Publicado: (2011)

Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
por: Espinosa, Lluís
Publicado: (2015)

Tumor microenvironment induces innate RAF-inhibitor resistance through HGF secretion
por: Straussman, Ravid, et al.
Publicado: (2012)

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
por: Tran, Timothy H., et al.
Publicado: (2021)

Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain
por: Travers, Timothy, et al.
Publicado: (2018)

STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma
por: He, Weiman, et al.
Publicado: (2023)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
por: Jones, Greg G., et al.
Publicado: (2019)

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
por: Shin, Seung-Min, et al.
Publicado: (2020)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018)

Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment
por: Deng, Shanshan, et al.
Publicado: (2020)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation
por: Cookis, Trinity, et al.
Publicado: (2021)

1044. Impact of Interdisciplinary Rounds on Antimicrobial Use at a Community Hospital
por: Castillo, Emma, et al.
Publicado: (2019)

Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan
por: Ikoma, Tatsuki, et al.
Publicado: (2021)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway
por: Wu, C-H, et al.
Publicado: (2002)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)

Interactome dynamics of RAF1-BRAF kinase monomers and dimers
por: Iglesias-Martinez, Luis F., et al.
Publicado: (2023)

BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition
por: Obasaju, Patience, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2fp1tm1e6l48p6n3otk34vdrum